To transform the treatment of androgenetic alopecia patients
through a targeted topical therapy that delivers powerful results and effortless application — with superior safety and tolerability.
And Beyond
Once achieved — to bring this precision topical therapeutic approach to patients with other skin conditions where current topicals fail.
What we developed. Why we are better.
Unbeatable efficacy, safety, and patient adherence — engineered into one formulation.
The Most Potent AGA Drug Combination
A proprietary combination of multiple proven actives — engineered to be safely co-delivered for synergistic, multi-mechanism efficacy that no existing therapy can match.
Follicle-Focused. Bloodstream-Protected.
Designed to act directly at the hair follicle while minimizing exposure to the rest of the body — avoiding the side effects associated with systemic absorption.
Slow Release. Smarter Dosing.
Steady multi-day release reduces dosing frequency from twice-daily to approximately once weekly — improving patient adherence with a smart, condition-responsive profile.
Every Step of AGA, Addressed in One Dose
A single formulation designed to address the multiple underlying drivers of androgenetic alopecia simultaneously — rather than targeting only one mechanism like existing therapies.
A biotech company developing precision topical therapies.
We are creating the next generation of targeted topical treatments — starting with androgenetic alopecia.
Foliven Pharma is an early-stage biotech company developing targeted topical therapies for dermatological conditions. Our lead product targets androgenetic alopecia (AGA) — one of the most prevalent dermatological conditions worldwide — where existing treatments struggle with limited efficacy, poor tolerability, and inconsistent results.
Our lead therapy is engineered to deliver multiple synergistic actives directly at the site of action, with sustained release and minimal systemic exposure. Beyond AGA, we are advancing additional therapies for skin conditions where conventional topicals fall short.
Partner with us.
We welcome conversations with investors, scientific collaborators, and dermatology-focused partners.